Galapagos Pledges More Restraint On Pipeline Potential

But Keeping The Faith With Toledo

The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."

false start
Galapagos hoping for no more false starts with its pipeline • Source: Alamy

More from Clinical Trials

More from R&D